Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677–92.

Article  CAS  PubMed  Google Scholar 

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.

Article  CAS  PubMed  Google Scholar 

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–57.

Article  CAS  PubMed  Google Scholar 

Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int. 2020;31:655–65.

Article  CAS  PubMed  Google Scholar 

Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag. 2016;12:1831–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Smerdely P. Hypocalcaemia after denosumab in older people following fracture. Osteoporos Int. 2017;28:517–22.

Article  CAS  PubMed  Google Scholar 

HIGHLIGHTS OF PRESCRIBING INFORMATION (Prolia® (denosumab)). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s213lbl.pdf. Accessed 14 Aug 2024.

Kim KJ, Hong N, Lee S, Kim M, Rhee Y. A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study. Calcif Tissue Int. 2020;107:567–75.

Article  CAS  PubMed  Google Scholar 

Isakova T, Anderson CA, Leonard MB, Xie D, Gutiérrez OM, Rosen LK, Theurer J, Bellovich K, Steigerwalt SP, Tang I, Anderson AH, Townsend RR, He J, Feldman HI, Wolf M. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant. 2011;26:1258–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41–50.

Article  CAS  PubMed  Google Scholar 

Noguchi Y, Tachi T, Teramachi H: Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems. Front Pharmacol. 2019;10:1319.

Goyal A, Anastasopoulou C, Ngu M, Singh S. Hypocalcemia. StatPearls: StatPearls Publishing; 2023.

Google Scholar 

Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009;27:635–42.

Article  CAS  PubMed  Google Scholar 

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

Article  CAS  PubMed  Google Scholar 

Krück F, Bablok W, Besenfelder E, Betzien G, Kaufmann B. Clinical and pharmacological investigations of the new saluretic azosemid. Eur J Clin Pharmacol. 1978;14:153–61.

Article  PubMed  Google Scholar 

Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–9.

Article  CAS  PubMed  Google Scholar 

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int. 2019;30:241–9.

Article  CAS  PubMed  Google Scholar 

Nakamura Y, Suzuki T, Kamimura M, Murakami K, Ikegami S, Uchiyama S, Kato H. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res. 2017;5:17021.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–23.

Article  CAS  PubMed  Google Scholar 

Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, Khan T, Muanda FT, Nash DM, Silver SA, Thain J, Weir MA, Garg AX, Clemens KK. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study. J Bone Miner Res. 2023;38:650–8.

Article  CAS  PubMed  Google Scholar 

Huynh AL, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25:1274–8.

Article  CAS  PubMed  Google Scholar 

Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104:44.

Google Scholar 

Ikegami K, Hashiguchi M, Kizaki H, Yasumuro O, Funakoshi R, Hori S. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D(3) )/Calcium Supplement. J Clin Pharmacol. 2022;62:1151–9.

Article  CAS  PubMed  Google Scholar 

Lombardi F, Paoletti L, Carrieri B, Dell’Aquila G, Fedecostante M, Di Muzio M, Corsonello A, Lattanzio F, Cherubini A. Underprescription of medications in older adults: causes, consequences and solutions-a narrative review. Eur Geriatr Med. 2021;12:453–62.

Article  CAS  PubMed  Google Scholar 

Bridgeman MB, Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther. 2011;33:1547–59.

Article  CAS  PubMed  Google Scholar 

Jalleh R, Basu G, Le Leu R, Jesudason S. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Rep Nephrol. 2018;2018:7384763.

PubMed  PubMed Central  Google Scholar 

Chandler PT, Chandler SA. Increased serum calcium levels induced by furosemide. South Med J. 1977;70:571–2.

Article  CAS  PubMed  Google Scholar 

Bushinsky DA, Favus MJ, Langman CB, Coe FL. Mechanism of chronic hypercalciuria with furosemide: increased calcium absorption. Am J Physiol. 1986;251:F17–24.

CAS  PubMed  Google Scholar 

Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail. 2002;4:167–73.

Article  CAS  PubMed  Google Scholar